In preclinical studies, the FLT3-targeted CAR-T cells successfully eliminated FLT3 positive AML cells (63, 64), and the FLT3 inhibitor crenolanib promoted their anti-tumor effects (64). The gene discussed is FLT3; the disease is neoplasm.